Objective:To investigate the effects of human placenta tablets combined with active folic acid and compound nutrient tablets on Th1 cytokines and hormone levels in pregnant patients with threatened miscarriage.Methods:A total of 226 pregnant patients with threatened miscarriage who received treatment in Linyi Traditional Chinese Medicine Hospital from April to September 2021 were included in this study. They were randomly divided into a control group and an observation group, with 113 patients in each group. The control group was treated with human placenta tablets. The observation group was treated with human placenta tablets combined with active folic acid and compound nutrient tablets. All patients were treated for 4 weeks. Before and after treatment, serum levels of Th1 cytokines, β-human chorionic gonadotropin, progesterone, and estradiol as well as the rate of success of protection against miscarriage, adverse reactions, and perinatal complications were compared between the two groups.Results:After 4 weeks of treatment, serum levels of interleukin-2, tumor necrosis factor-α, and interferon-γ in the observation group were significantly lower than those in the control group ( t = 27.53, 20.99, 31.69, all P < 0.001). Serum levels of β-human chorionic gonadotropin, progesterone, and estradiol in the observation group were (143.79 ± 9.56) IU/L, (36.43 ± 4.71) ng/L, (234.72 ± 13.29) pmol/L, which were significantly higher than (122.53 ± 7.47) IU/L, (29.32 ± 4.22) ) ng/L, (167.86 ± 8.93) pmol/L in the control group ( t = 18.63, 11.95, 44.39, all P < 0.001). The rate of success of protection against miscarriage in the observation group was significantly higher than that in the control group (92.9% vs. 76.1%, χ2 = 12.20, P < 0.05). There were no significant differences in the incidences of adverse reactions and perinatal compilations between the two groups (both P > 0.05). Conclusion:Human placenta tablets combined with active folic acid and compound nutrient tablets can improve serum levels of Th1 cytokines and hormones, and increase the rate of success of protection against miscarriage, without increasing the incidences of adverse reactions and perinatal complications.